# PRESS RELEASE

**Cell4Cure Secures U.S. Trademark Registration**

**Solna, Stockholm Region, Sweden – November 25, 2026 – Cell4Cure AB today announced that its company logo has been officially registered as a trademark with the United States Patent and Trademark Office (USPTO).**

The registration, U.S. Trademark Registration No. 8,528,826, was granted on November 3, 2026, providing trademark protection in the United States for Cell4Cure's distinctive logo, featuring the CELL4CURE name and the tagline "PERSONALIZED TOLERANCE" together with its graphical design elements.

The registration covers Class 42 services, including research and development in immunology, biotechnology, pharmaceutical development, cell and gene therapies, and related fields.

The successful registration represents another step in strengthening Cell4Cure's international corporate identity and supporting the company's presence in the U.S. market.

For more information, please contact:

**Christina Herder, CEO**
Telephone: +46703747156
Email: christina.herder@cell4cure.com

**About Cell4Cure**
Founded in 2023, Cell4Cure AB is a Swedish biotech company pioneering immune tolerance therapies to address critical challenges such as anti-drug antibodies (ADAs), autoimmune diseases, and transplant rejection. The company’s proprietary platform is based on ex vivo-engineered dendritic cells (DCs) designed to induce antigen-specific immune tolerance while preserving essential immune function. Backed by $30 million in research and development investments, Cell4Cure has achieved key milestones, including European Medicines Agency (EMA) approval for clinical trials and the establishment of robust GMP manufacturing processes.

**Cell4Cure AB** | Org nr: 559445-7979
Gustav III:s Boulevard, 16972 Solna, Sweden
Website: www.cell4cure.com
Cell4Cure | LinkedIn